| Seamless Therapeutics–Trophic Communications: public relations, 202303 service existent by Trophic |
2023-03-16 |
| Seamless Therapeutics–Wellington Partners: investment, 202303 seed financing round totalling €7.9m incl co-lead investor Wellington Partners |
2023-03-16 |
| Turnstone Biologics–Scailyte: biomarker discovery, 202303– collab biomarker discovery for TIL therapy using ScaiVision platform |
2023-03-16 |
| Mediar Therapeutics–Novartis: investment, 202303c financing round Series A totalling $85m incl co-lead investor Novartis Venture Fund |
2023-03-15 |
| Mediar Therapeutics–SEVERAL: investment, 202303c financing round Series A $85m co-led by NVF + Sofinnova Partners |
2023-03-15 |
| Iktos–Debiopharm: investment, 202303 financing round Series A totalling €15.5m incl new + co-lead investor Debiopharm Innovation Fund |
2023-03-09 |
| Iktos–Merck (DE): investment, 202303 financing round Series A totalling €15.5m incl new + co-lead investor M Ventures |
2023-03-09 |
| Iktos–Omnes Capital: investment, 202303 financing round Series A totalling €15.5m incl co-investor Omnes Capital |
2023-03-09 |
| Iktos–SEVERAL: investment, 202303 financing round Series A €15.5m co-led by M Ventures + Debiopharm Innovation Fund |
2023-03-09 |
| Cellbox Solutions–SEVERAL: investment, 202303 financing round Series A1 €6.5m led by CK Ventures |
2023-03-07 |
| Noema Pharma–SEVERAL: investment, 202303 financing round Series B CHF103m ($12m) co-led by Forbion + Jeito Capital |
2023-03-07 |
| Calibre Scientific–Eppendorf: micromanipulation products, 202303 acquistion of micro manipulation product portfolio of Eppendorf by Calibre Scientific |
2023-03-06 |
| Confo Therapeutics–Trophic Communications: public relations, 202303 service existent by Trophic |
2023-03-02 |
| Simulands–SHS Capital: investment, 202303 investment €10m in Simulands by SHS |
2023-03-02 |
| BioNTech–Weizmann Institute: mRNA technology, 202303– collab research in Israel with new BioNTech nRNA Excellence Center MOU |
2023-03-01 |
| Bico–ABB: laboratory automation equipment, 202302 collab product integration Nucleus Automation Ecosystem + sciFLEXARRAYER of Scienion + ABB Robotics |
2023-02-27 |
| VisionHealth–Bruchmann Group: investment, 202302 financing round pre-Series A totalling €3m incl new + lead investor DB Speciality Invest |
2023-02-27 |
| VisionHealth–SEVERAL: investment, 202302 financing round pre-Series A €3m led by DB Speciality Invest |
2023-02-27 |
| Akttya Therapeutics–CrystalsFirst: drug discovery services, 202302– supply service €na using SmartSoak technology on novel protein targets of Akttyva |
2023-02-23 |
| Prosion–Collaborative Drug Discovery: data management software, 202302– supply service Prosion to use CDD Vault to host its RnD data |
2023-02-23 |
| Paleo–Planet A: investment, 202302 financing round Series A totalling €12m incl co-lead investor Planet A Ventures |
2023-02-22 |
| Paleo–SEVERAL: investment, 202302 financing round Series A €12m led by DSM Venturing + Planet A Ventures |
2023-02-22 |
| Resalis Therapeutics–Trophic Communications: public relations, 202302 service existent by Trophic |
2023-02-22 |
| Alentis Therapeutics–O Public Relations: public relations, 202302 service existent by O Public Relations |
2023-02-17 |
| Lift BioSciences–Resonac: biologics contract manufacturing, 202302– collab developm + manufacturing of N-LIfT for clinical trials by Minaris RM |
2023-02-16 |
| Hexagon Bio–Nextech: investment, 202302 financing round Series B totalling $77.3m incl existing investor Nextech |
2023-02-13 |
| Hexagon Bio–SEVERAL: investment, 202302 financing round Series B $77.3m from existing + new investors |
2023-02-13 |
| Life Science Valley–Lower Saxony (govt): investment, 202302 fund launch with total of €12m incl €6m from NBank |
2023-02-13 |
| Life Science Valley–Sartorius: investment, 202302 fund launch with total of €12m incl €6m from Sartorius + Univ Medical Center Göttingen combined |
2023-02-13 |
| Life Science Valley–SEVERAL: investment, 202302 fund launch with €12m incl €6m from Niedersachsen + remainder from Sartorius + Univ Göttingen |
2023-02-13 |
| Life Science Valley–Univ Göttingen: investment, 202302 fund launch with total of €12m incl €6m from Univ Medical Center Göttingen + Sartorius combined |
2023-02-13 |
| Freeline Therapeutics–Ascend GCTx: investment, 202302 acquisition of Freeline Therapeutics GmbH for $25m by Ascend GCTx Ltd |
2023-02-10 |
| AMSilk–BRAIN Biotech: biomaterials, 202302– strategic collaboration development of high-performance bio-based protein fibers |
2023-02-08 |
| APK–SEVERAL: investment, 202302– financing round €130m incl minority investments from LyondellBasell + KIRKBI A/S |
2023-02-08 |
| BrainRepair–OTHER: investment, 202302 investment €50m for 20% of shares of BrainRepair UG by London-based group |
2023-02-08 |
| Danaher–Seed Biosciences: cell dispenser, 202302– distribution excl of DinspenCell in US + Asia + resale in Europe by Molecular Devices |
2023-02-07 |
| CureVac–SEVERAL: investment, 202302 public offering $250m+$37.5m with 27m+4.05m common shares at $9.25/share |
2023-02-06 |
| JnJ–Evotec: cancer immunotherapy, 202301– strategic collab + license agreem developm first-in-class targeted immune-based cancer therapies |
2023-01-26 |
| Refined Laser Systems–Apex Ventures: investment, 202301 seed financing round totalling €2.7m incl co-lead investor Apex Medical Fund |
2023-01-26 |
| Refined Laser Systems–High-Tech Gründerfonds: investment, 202301 seed financing round totalling €2.7m incl co-lead investor HTGF |
2023-01-26 |
| Refined Laser Systems–North Rhine-Westphalia (govt): investment, 202301 seed financing round totalling €2.7m incl co-investor NRW.Bank |
2023-01-26 |
| Refined Laser Systems–Onsight Ventures: investment, 202301 seed financing round totalling €2.7m incl co-investor Onsight Ventures |
2023-01-26 |
| Refined Laser Systems–Papst: investment, 202301 seed financing round totalling €2.7m incl co-investor Papst Venture Capital |
2023-01-26 |
| Refined Laser Systems–PERSON: investment, 202301 seed financing round totalling €2.7m incl private investors T Merk + HM Hauser + W Falkenstein |
2023-01-26 |
| Refined Laser Systems–SEVERAL: investment, 202301 seed financing round €2.7m led by HTGF + Apex Ventures |
2023-01-26 |
| Novartis–Astellas: micafungin, 202110– acquisition of ww product rights to Mycamine/Funguard by Sandoz from Astellas SIGNED |
2023-01-24 |
| Agilent–Plasmion: ionisation technology, 202301– collab co-marketing of SICRIT ion source with Agilent Ultivo LC/TQ + LC/MSD iQ MS systems |
2023-01-18 |
| Blackford Analysis–Bayer: investment, 202301–202302 acquisition by Bayer |
2023-01-18 |
| Siemens–ASG Superconductors: magnetic resonance imaging, 202301– collab integration of ASG MRI magnets >7T in Siemens Healthineers UFH MRI systems |
2023-01-18 |
| Bayer–Alphabet: cloud computing services, 202301– collab using Google Cloud TPUs for quantum chemitry calculations in drug discovery |
2023-01-11 |
| Boehringer–Minapharm: rec protein production technology, 202301– collab non-excl €na of ProBioGen + Boehringer on DirectedLuck transposase technology |
2023-01-10 |
| NextPoint Therapeutics–Bayer: investment, 202301 financing round Series B totalling $80m incl new + co-lead investor Leaps by Bayer |
2023-01-10 |
| NextPoint Therapeutics–Sanofi: investment, 202301 financing round Series B totalling $80m incl new + co-lead investor Sanofi Ventures |
2023-01-10 |
| NextPoint Therapeutics–SEVERAL: investment, 202301 financing round Series B $80m co-led by Leaps by Bayer + Sanofi Ventures |
2023-01-10 |
| Boehringer–3T Biosciences: cancer immunotherapies, 202301– strategic collab + license agreem RnD of cancer therapies using 3T-TRACE discovery platform |
2023-01-09 |
| Proteros–Inflexion: investment, 202301– minority investment by Inflexion with founder + CEO Torsten Neuefeind remaing majority shareholder + CEO |
2023-01-09 |
| Verogen–Qiagen: investment, 202301c full acquisition of Verogen for $150m in cash |
2023-01-09 |
| Acquifer Imaging–Bruker: investment, 202301 acquisition €na of Acquifer Imaging Gmbh + subsidiary Deltabyte GmbH by Bruker |
2023-01-05 |
| BioVersys–AMR Action Fund: investment, 202301 financing round Series C extension with CHF8.2m? from AMR AF bringing total Series C to CHF32.6m |
2023-01-05 |
| Biognosys–Bruker: investment, 202301 acquisition €na of majority share in Biognosys by Bruker |
2023-01-04 |
| Hummingbird Bioscience–Synaffix: ADC technology, 202301– license to GlycoConnect + HydraSpace + toxSYN technoligies up to $150m plus royalties |
2023-01-04 |
| Mysthera Therapeutics–Forty51 Ventures: investment, 202308 seed financing $3.5m from Forty51 Ventures announced |
2023-01-01 |
| Mysthera Therapeutics–Inflection Biosciences: PAM kinase inhibitors, 2023– license to Mysthera from Inflection |
2023-01-01 |
| Seamless Therapeutics–Germany (govt): grant, 202301–202512 GO-Bio Phase II grant €3.9m from BMBF |
2023-01-01 |
| Selfapy–Berlin (govt): investment, 202212 financing round totalling €7m incl existing + co-investor IBB Ventures |
2022-12-23 |
| Selfapy–High-Tech Gründerfonds: investment, 202212 financing round totalling €7m incl existing + co-investor HTGF |
2022-12-23 |
| Selfapy–Medice: investment, 202212 financing round totalling €7m incl new + lead investor Medice Arzneimittel |
2022-12-23 |
| Selfapy–SEVERAL: investment, 202212 financing round €7m led by new investor Medice Arzneimittel plus all existing investors |
2022-12-23 |
| Selfapy–SHS: investment, 202212 financing round totalling €7m incl existing + co-investor SHS |
2022-12-23 |
| Selfapy–Think.Health: investment, 202212 financing round totalling €7m incl existing + co-investor Think.Health Ventures |
2022-12-23 |
| Merck (DE)–Mersana: ADC technology, 202212– collab €30m upfront + $800m milestones + royalties using Immunosynthen platform for STING-agonist ADCs |
2022-12-22 |
| IsoPlexis–Berkeley Lights: investment, 202212–202303 merger acquisition $57.8m in shares with former Berkeley owners holding 75.2%, renamed PhenomeX |
2022-12-21 |
| Numares–EU (govt): credit, 202212– quasi-equity venture debt financing up to €20m from EIB |
2022-12-20 |
| Numares–SEVERAL: investment, 202212 financing round €20m from existing investors |
2022-12-20 |
| Boehringer–Click Therapeutics: digital therapeutics, 202212– collab expansion to develop 2nd DTx for schizophrenia up to $460m + royalties |
2022-12-19 |
| S-Biomedic–Beiersdorf: investment, 202212 acquisition €na of majority share in S-Biomedic NV by Beiersdorf AG |
2022-12-16 |
| Minervax–Bellevue: investment, 202212 financing round totalling €22m incl new + co-lead investor Pureos Bioventures |
2022-12-15 |
| Minervax–Novo Group: investment, 202212 financing round totalling €22m incl exisiting + co-investor Novo REPAIR Impact Fund |
2022-12-15 |
| Minervax–SEVERAL: investment, 202212 financing round €22m co-led by Trill Impact Ventures + Pureos Bioventures |
2022-12-15 |
| Minervax–Sunstone Life Science: investment, 202212 financing round totalling €22m incl exisiting + co-investor Sunstone Life Science Ventures |
2022-12-15 |
| Minervax–Wellington Partners: investment, 202212 financing round totalling €22m incl exisiting + co-investor Wellington Partners |
2022-12-15 |
| Storm Therapeutics–Merck (DE): investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor M Ventures |
2022-12-14 |
| Storm Therapeutics–SEVERAL: investment, 202212 financing round Series B $30m led by M Ventures + Pfizer Ventures + Taiho Ventures + CIC |
2022-12-14 |
| Merck (DE)–Synplogen: viral vectors, 202212– collab MoU integration of offerings for viral vector dev + production for gene therapies in Japan |
2022-12-13 |
| Icosagen–Genedata: bioinformatics, 202212– supply deployment of GeneData Biologics by Icosagen |
2022-12-12 |
| Bico–Sartorius: investment, 202212– directed share issue SEK487m (€45m) to existing investor Sartorius resulting 10.1% share + 8.5% of voting rights |
2022-12-08 |
| Ryvu Therapeutics–Augebit FIZ: investment, 202212 public offering totalling PLN250.3m incl PLN13m from Augebit FIZ fund |
2022-12-08 |
| Ryvu Therapeutics–Leukemia & Lymphoma Society: investment, 202212 public offering totalling PLN250.3m incl PLN4.5m from LLS TAP |
2022-12-08 |
| Ryvu Therapeutics–PERSON: investment, 202212 public offering totalling PLN250.3m incl PLN10m from co-founder + CEO + largest owner P Przewiezlikowski |
2022-12-08 |
| Ryvu Therapeutics–SEVERAL: investment, 202212 public offering PLN250.3m of 4.8m Series J common shares led by BioNTech |
2022-12-08 |
| Sartorius–Bico: laboratory equipment, 202212– collab RnD 3D cell printing technologies + digital soluitons for cell line development workflows |
2022-12-08 |
| Sartorius–Bico: laboratory equipment, 202212– distribution of Bico products in APAC region by Sartorius |
2022-12-08 |
| Variolytics–SEVERAL: investment, 202212 seed financing round €7-digit from HTGF + FTTF + business angels |
2022-12-07 |
| Xpress Biologics–Polyplus-transfection: investment, 202212 acquisition of Xpress Biologics by Polyplus from ArchiMed et al |
2022-12-07 |
| Erbi Biosytems–Merck (DE): investment, 202212 acquisition €na of Erbi Biosystems by Merck |
2022-12-01 |
| BioNTech–Ryvu Therapeutics: small molecule immuno modulators, 202211– collab + license €20m upfront + research funding + milestones + royalties |
2022-11-30 |
| Ryvu Therapeutics–BioNTech: investment, 202212 public offering totalling PLN250.3m incl PLN94m (€20m) from lead investor BioNTech related to collab |
2022-11-30 |
| Cajal Neuroscience–Evotec: investment, 202211 financing round Series A totalling $96m incl existing + co-investor Evotec |
2022-11-29 |
| Cajal Neuroscience–SEVERAL: investment, 202211 financing round Series A $96m led by The Column Group + Lux Capital |
2022-11-29 |
| Rgenta Therapeutics–SEVERAL: investment, 202211 financing round Series A $52m led by AZ-CICC Healthcare Investment Fund |
2022-11-29 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 4 5 ... 42 43 44 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
